Tracking breast cancer treatment outcomes in real patients
NCT ID NCT06797531
Summary
This study follows 177 patients in Saudi Arabia who are already taking ribociclib plus hormone therapy for early-stage breast cancer. Researchers will observe how well the treatment works and what side effects occur in real-world medical practice over 3 years. The study doesn't change anyone's treatment—it simply tracks outcomes from routine care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11426, Saudi Arabia
Conditions
Explore the condition pages connected to this study.